Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Trading at a bit under $25 apiece, Pfizer 's (NYSE: PFE) shares appear tentatively cheap. However, the pharmaceutical giant reached these levels because it has faced significant headwinds, resulting ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the ...

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...

Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer's acquisitions haven't paid off yet and the company is still struggling to grow its sales. The two ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.